Cargando…
Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could r...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228175/ https://www.ncbi.nlm.nih.gov/pubmed/37287613 http://dx.doi.org/10.1016/j.heliyon.2023.e16664 |